| 27.56 |  +0.12 / +0.44% |
Data as of 4:00pm ET | Day’s Change |
| 27.52 |  -0.0356 / -0.13% |
Volume: 11,000 |
| Alnylam Narrows Loss, Sales Fall - Analyst Blog May 07 / Zacks.com |
| Previous close | 27.44 |
| Today’s open | 27.24 |
| Day’s range | 27.24 - 27.75 |
| Volume | 259,236 |
| Average volume (3 months) | 441,712 |
| Market cap | $1.7B |
| Dividend yield | -- |
| Earnings growth (last year) | -55.15% |
| Earnings growth (this year) | +38.66% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -19.37% |
| P/E ratio | NM |
| Price/Sales | 13.75 |
| Price/Book | 10.74 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABCOAdvisory Board Co | +0.39 | +0.78% |
| ICLRICON PLC | +0.01 | +0.03% |
| CRLCharles River Labora... | -0.10 | -0.22% |
| LXRXLexicon Pharmaceutic... | -0.03 | -1.36% |
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.34 |
| Annual revenue (last year) | $66.7M |
| Annual profit (last year) | -$106.0M |
| Net profit margin | -158.88% |
Sector Health Technology |
Industry Biotechnology |
Chairman John K. Clarke, MBA |
President & Chief Operating Officer Barry E. Greene |
Corporate headquarters Cambridge, Massachusetts |
.
